Beijing Friendship Hospital reports oveporexton prescribing for type 1 narcolepsy

Beijing Friendship Hospital has reported a prescription of oveporexton tablets for a patient with type 1 narcolepsy. Neurologist Tuo Houzhen issued the prescription on October 15 after a detailed review and assessment of the patient's condition. The hospital published the account on October 22, 2026, describing an actual step into clinical prescribing.

The condition and the treatment's target

The hospital states that China's National Medical Products Administration approved the medicine on July 23, 2026, for adolescents and adults aged 16 and over with type 1 narcolepsy. Oveporexton is an oral, highly selective orexin type 2 receptor (OX2R) agonist.

Type 1 narcolepsy involves a major loss of orexin-producing neurons in the hypothalamus. Insufficient orexin signalling makes wakefulness and the sleep–wake state unstable. Symptoms can include excessive daytime sleepiness, recurrent emotion-triggered cataplexy and fragmented nighttime sleep.

The hospital contrasts previous symptom-focused treatment with this medicine's action on the orexin pathway. By activating OX2R, it is intended to compensate for deficient orexin signalling and help stabilise sleep and wakefulness, with effects on wakefulness, daytime sleepiness and cataplexy. This mechanism should not be read as restoration of lost neurons or a cure. The reported indication remains type 1 narcolepsy and the stated age group.

A prescription-based access route at Xicheng

The hospital says its Xicheng campus dual-channel pharmacy has stocked the medicine. Clinicians can issue a dual-channel prescription, providing a route to obtain it. The report links this arrangement to Beijing's 2025 measures supporting the introduction of innovative medicines and devices into municipal hospitals, including class I innovative medicines.

For a patient seeking care in China, the concrete news is the documented prescribing and pharmacy route, coupled with a defined diagnosis and age indication. The medicine was prescribed after a physician's assessment, rather than offered as an unrestricted purchase.

The account does not report this patient's response after taking the medicine. Availability through the described pharmacy does not by itself establish an overseas patient's eligibility, insurance reimbursement or permission to carry medication across a border. Those matters cannot be inferred from the first-prescription announcement.